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THE proliferation rate of vascular endo-
thelial cells in tumours exceeds that in
most adult normal tissues by a very large
factor, often greater than 20 (Figure).
This enormous differential offers a poten-
tial route for aiming tumour therapy at
solid tumours by means of a targeted
systemic toxin, with little risk of damage
to most of the normal tissues.
It has long been recognized that one of
the major differences between solid
tumours and adult normal tissues is the
pattern and rate of development of the
vascular network. New vessel formation
in tumours is rapid, but it is insufficient,
particularly in a 3-dimensional arrange-
ment, to provide an adequate nutrient
supply to all the tumour cells (Hirst et al.,
1982). For this reason many tumour cells
are non-proliferating because of nutrient
deprivation, and hypoxic because of
oxygen depletion by the metabolizing
tumour cells around each capillary. This
produces resistance to both chemotherapy
and radiotherapy. A great deal ofresearch
is devoted to finding ways of improving
the oxygenation, proliferative status and
drug delivery in such tumours.
Folkman and co-workers (Folkman et
al., 1971; Folkman, 1974, 1975) have
recognized the special ability of tumour
cells to promote new vessel formation via
the tumour angiogenesis factor (TAF).
They have proposed methodsofpreventing
tumour growth by interfering with angio-
genesis, including an immunological tech-
nique for inactivating TAF by producing
an anti-TAF antibody which would pre-
vent further capillary proliferation.
Elsewhere, little attention has been
paid to the enormous differential between
the proliferation characteristics of the
tumour vasculature and the normal tissue
vasculature. Tannock (1970), Hirst &
Denekamp (1979) and Hirst et al. (1982)
have compared the proliferation rate of
the capillary endothelium in tumours with
that of the tumour cells themselves. They
concluded that the rate of endothelial
proliferation limits tumour cell produc-
tion even though as many as 18% of the
endothelial cells can be in DNA synthesis
at any one time.
Other studies have concentrated on the
very low proliferation rate of endothelial
cells in a variety of normal tissues (see
reviews by Tannock & Hayashi, 1972;
Hirst et al., 1980). However, the remark-
able difference in proliferation rates be-
tween endothelium in tumours and in
normal tissues does not seem to have been
previously commented upon or identified
as a potential route for directing therapy
at a tumour.
The Table summarizes the published
labelling index (LI) for normal tissue and
tumour endothelium, and illustrates the
large difference between them. The values
shown were obtained by scoring auto-
radiographs of tissues sampled 1 h-I h
after a single injection of the DNA
precursor, [3H]dT. A mean LI of 0.6% is
obtained for normal tissue endothelium,
by averaging all the values reviewed byENDOTHELIAL CELLS AS TUMOUR TARGET
TABLE.-Proliferation of vascular endothelium in tumours and normal tissues
Normal tissues
Aorta
(Mean of 7 studies)
Arteries & Veins
(Mean of 6 studies)
Capillaries
(Mean of 14 studies)
Tumours
C3H mammary carcinoma
C3H carcinoma KHH
C3H carcinoma KHU
WHT carcinoma RH
LI (%)
0-61
0-82
0-56
11 -4
17-7
17 -9
4-5
Potential
turnover time
(Days)
55
41
60
(Hours)
55
45
45
178
Volume
doubling time
(Days) Reference
00
T Reviewed by
Tannock & Hayashi, 1972;
oo Hirst et al., 1980
2-5
5
6
13 }
Tannock, 1970
Hirst et al., 1982
The potential turnover time is calculated as ATs/LI (assuming A=0-8 and Ts = 10 h) where A is a correction
factor for the non-linear distribution of cells throughout the phases of the cell cycle (Steel, 1968).
Tannock & Hayashi (1972) and Hirst et al.
(1980) for a wide range of normal tissues.
It does not differ much between major
vessels and capillaries. Most authors have
indicatedextremelylowproliferative activ-
ity in normal tissue endothelium, with
half the studies showing an LI<0.25%.
The highest recorded value is 3.4% for
adult rat mesenteric vessels (Crane &
Dutta, 1964) but this contrasts markedly
with 0.45% for the same tissue in mice
(Hirst et al., 1980).
Fewer data have been published for
tumours; these are also summarized in the
Table. The lowest LI is 4.5% for the
exceptionally slow-growing mouse tumour
CA RH (Hirst et al., 1982) and two of the
tumours have values approaching 18%.
This difference between tumours and
normal tissues is illustrated even more
dramatically in the Figure. Some addi-
tional data are included for rat and mouse
tumours (Denekamp & Hobson, inprepara-
tion) which show a range from 3.5% for
lymphoma KHAA (which grows by infil-
tration rather than by evoking a neo-
vasculature) to 32.5% for the rapidly
growing rat fibrosarcoma RIB5. The
mean of the endothelial LI values in
tumours is more than 20-fold that for
normal tissues and there is hardly any
overlap of the histograms.
With the advent of sophisticated im-
munological techniques, including mono-
clonal antibodies, it seems likely that
FIGURE.-Vascular endothelial cell prolifer
ation. A histogram showing the number
of studies in normal tissues and in tumours
with particular values for the labelling
index of endothelial cells f-i h after a
single injection of [3H]dT. Half of the
normal-tissue studies P show values below
0.25% with a mean LI of 0.6%. The
range for tumours U is from 3X5-32.5%
with a mean of 13;5%. There is a very
large differential in these LI values with
almost no overlap.
this tremendous proliferative differential
could be exploited. An immuno-histo-
chemical technique is already in use to
identify endothelial cells in histological
preparations, by means of Factor VIII
antigen (Hoyer et al., 1973) and mono-
clonal antibodies have recently been
raised against this antigen (Sola et al.,
1981). It should be possible to conjugate
an S-phase-specific chemotherapeutic
agent with an endothelial-cell-specific
antibody, which could result in a large
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degree of cell killing in tumour capillaries
with very little damage to any normal
tissue vessels. It is also conceivable that
antibodies could be raised more specific-
ally against proliferating endothelial cells,
as distinct from all other endothelial cells.
These could then be conjugated with any
potent cell toxin (e.g. abrin or ricin) which
would be released at the desired site of
action. Proliferating endothelial cells can
be produced very readily in vivo as a
granulomatous response to an irritant;
this would provide a richer and easier
source of dividing endothelium than
tumour vessels for raising antibodies
This approach, directing tumour therapy
via the proliferating endothelium, would
avoid the necessity for identifying a
tumour-specific antigen. It could provide
a means of attacking solid tumours,
including small metastases, via a universal
pathway which is already known to be
the weak point in tumour development. It
would need to be used in combination with
radiation and/or chemotherapy, and the
sequencing would be very important. As
vessels become occluded or collapse the
surrounding cells would become more
deficient in nutrients and oxygen and
hence more chemo- andradiation-resistant.
The possible influx of endothelial cells
from the general circulation would also
need to be studied, but this seems to be a
relatively slow process (Hobson et al.,
1980).
Potential side effects, of course, would
need a very thorough investigation in
animals. Fresh wound tissue, premeno-
pausal endometrium and placenta, are all
tissues in which a highlv proliferative
endothelium will exist, and these would
probably be at risk. Patients undergoing
surgery, pregnant women, or those in the
initial proliferative phase of each oestrus
cycle, would therefore be unsuitable for
this form of therapy. However, anti-
proliferating-endothelium therapy (APET)
would be likely to be of only a few days
duration to injure most of the tumour
endothelium, as judged from the potential
turnover-time estimates for tumour endo-
thelium, at least for rodent tumours
(Table). The demonstration of equally
high Lls for endothelium in human
tumours would of course be crucial for this
approach to have a clinical future. This
information should be readily obtainable
with biopsy material and in vitro incuba-
tion (Denekamp & Kallman, 1973).
A small loss of endothelial cells in
normal tissues is unlikely to be of major
significance. Radiation studies on mesen-
teric arterioles have shown that the
endothelium can be gradually depleted to
10-20% ofits normal cell number without
any thrombosis or failure of vessel func-
tion. (Hirst et al., 1980). This functional
reserve probably results from the well-
developed sub-endothelial layers in normal
blood vessels, which are notably lacking
in most tumour vessels. It is not known
how catastrophic the loss of 50% or 90%
of the tumour endothelial cells would be,
but it is possible that the already poor
nturient supply would collapse and lead
to massive tumour-cell necrosis.
We are currently studying a variety of
other tumours and normal tissues. We
are using repeated doses of [3H]dT to
determine how many sequential injections
are needed to label all the endothelial
cells. Preliminary data indicate that the
20-fold difference between tumour and
normal vessels persists after one week of
continuous labelling (Denekamp & Hobson
unpublished). From these data it should
be possible to predict how long an APET
treatment with an S-phase-specific endo-
thelial toxin would be needed to affect a
given proportion of the endothelial cells in
tumour capillaries.
I am very grateful to Mrs B. Hobson for her
excellent assistance and to the Cancer Research
Campaign for their financial support.
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